MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre analyze To judge multiple intravenous doses of sifalimumab, in adult patients with dermatomyositis or polymyositis (NCT00533091). Major trial objectives were to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositis patients, although on the list of exploratory https://stephene554ugr8.hyperionwiki.com/user